Andy Chapman

Andy Chapman

Andy Chapman

Andy has a PhD in chemistry from the University of Bristol and has a mixed background in academic and industrial positions.

He left his position as Senior Lecturer at Kingston University London and Joined Ziylo in 2017 as CSO. In the same year he was appointed to the board of directors. In 2018 Ziylo was acquired by Novo Nordisk to use Ziylo’s Glucose Binding Molecule technology to develop for a therapeutic application.

Andy and the other board members founded Carbometrics after the acquisition, of which he is now CEO. Carbometrics was founded to commercialize the same Glucose Binding Molecule technology y for diagnostic applications and collaborate with Novo Nordisk to help develop the therapeutic application.